MedTrace Logo

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

NCT00605267 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2012-09-06

Study results available
· View outcomes & findings →

Summary

The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients

Conditions

Interventions

DRUG

Tamoxifen

20 mg once daily oral dose

DRUG

Anastrazole (Arimidex)

1 mg once daily oral dose

DRUG

Goserelin acetate (Zoladex)

3.6mg/month depot injection

Sponsors & Collaborators

Principal Investigators

  • Toshiyuki Kihara · Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-11-30
Completion
2010-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605267 on ClinicalTrials.gov